We were unable to process your request. Please try again later. If you continue to have this issue please contact [email protected]. The primary endpoint was the mean change in best ...

Results from a planned interim analysis of the SERENA-6 Phase III trial showed that AstraZeneca’s (AZN) camizestrant in combination with a cyclin-dependent kinase 4/6 inhibitor demonstrated a ...